It was a pleasure to speak to our Expert Faculty member, Dr Gil Y Melmed (Cedars-Sinai Medical Center, Los Angeles, CA, US), around the ADVANCE and MOTIVATE studies, which investigated risankizumab in the treatment of Crohn’s disease.
Questions
- Could you tell us a little about the aims, design and patient populations of the ADVANCE and MOTIVATE studies? (0:10)
- What were the findings of the ADVANCE and MOTIVATE studies? (1:42)
- What questions remain unanswered? (2:47)
Disclosures: Gil Y Melmed has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
